Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556253 | 0.78 | SMN1; SMN2 (0.38) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL556916 | 0.78 | CA1 (0.57) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL5026807 | 0.75 | CA2 (0.70) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL557323 | 0.73 | CA1 (0.49) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL557324 | 0.73 | CA1 (0.49) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL557322 | 0.73 | CA1 (0.49) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL22322001 | 0.73 | CA2 (0.55) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL22322000 | 0.71 | CA2 (0.57) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL1790783 | 0.71 | CA1 (0.57) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL557184 | 0.71 | CA2 (0.44) | CA2CA1BCHEACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | STAT3, JAK2, STAT6 | CA2 4451/4885CA1 4749/4885BCHE 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.